Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy

Journal of Medical Virology

Volumn 78, Issue 3, 2006, Pages 324-328

  Zhang, Ji Hing ^a,b,c   Wang, Xin Yu ^b   Huang, Yu Xian ^b   Yin, You Kuan ^b   Guan, Shihe ^a   Xu, Yang ^a,d   Roggendorf, Michael ^a   Lu, Mengji ^a,d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Fatal liver failure; HBsAg mutants; Hepatitis B virus; Lamivudine

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; CONSULTATION; DISEASE ASSOCIATION; DNA SEQUENCE; DOSE TIME EFFECT RELATION; DRUG SELECTIVITY; DRUG WITHDRAWAL; GENE MUTATION; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; MALE; NUCLEOTIDE SEQUENCE; VIRUS ISOLATION; VIRUS MUTANT; VIRUS REPLICATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA, VIRAL; FATAL OUTCOME; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FAILURE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 33644645263     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20543     Document Type: Article

References (20)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
2. Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY, Locarnini S. 2003. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J Clin Virol 27:111-116.
3. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. 1999. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28:1032-1035.
4. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. 1998. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. J Clin Invest 102(5):968-975.
5. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. 2001. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 33:963-971.
6. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
7. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. 2003. Histological outcome during long-term lamivudine therapy. Gastroenterology 124:105-117.
8. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. 2000. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32:847-851.
9. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. 2000. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 32:635-639.
10. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828-884.
11. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527-1532.
12. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
13. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172-180.
14. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
15. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov NV, Ferrari C, Bertoletti A. 2000. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191:1269-1280.
16. Marinos G, Naoumov NV, Williams R. 1996. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 24:991-995.
17. Mathet VL, Feld M, Espinola L, Sanchez DO, Ruiz V, Mando O, Carballal G, Quarleri JF, D'Mello F, Howard CR, Oubina JR. 2003. Hepatitis B virus S gene mutants in a patient with chronic active hepatitis with circulating Anti-HBs antibodies. J Med Virol 69:18-26.
18. Perrillo RP. 2001. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120:1009-1022.
19. Weinberger KM, Zoulek G, Bauer T, Bohm S, Jilg W. 1999. A novel deletion mutant of hepatitis B virus surface antigen. J Med Virol 58:105-110.
20. Yuen MF, Wong DK, Yuan HJ, Sum SM, Lai CL. 2004. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. J Clin Microbiol 42:4882-4884.